Last October 4th at the Hotel Principe di Lazise, there was a presentation to the entire Future Live Medical Information network of Decand, of an innovative nutraceutical based on Saccharomyces Cerevisiae CNCM I 3856, with specific adjuvant activity of antifungal therapy during candida vaginitis.

Decand contains Saccharomyces Cerevisiae CNCM I 3856, a particular yeast strain, selected and studied in France from over 6,000 species and deposited at the Pasteur Institute in Paris, This innovative yeast has been studied at microbiological and clinical level and has demonstrated the ability to protect the flora vaginal from the aggressions of potentially pathogenic yeasts such as Candida albicans.

Among the various speakers was Dr. Eva Pericolini, a microbiologist at the University of Modena, who illustrated the peculiar characteristics of this yeast in light of the studies carried out at her institution.

Future Live is currently involved in presenting Decand to medical specialists throughout the country.